BFM
EPRX

Boothbay Fund Management’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Boothbay Fund Management’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.34M Buy
323,843
+167,512
+107% +$1.35M 0.03% 552
2025
Q4 		$1.18M Buy
+156,331
New +$963K 0.02% 737

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Boothbay Fund Management's EPRX Position: Q1 2026 in Review

Boothbay Fund Management increased its Eupraxia Pharmaceuticals (EPRX) stake by 107% in Q1 2026, buying an estimated $1.35M and bringing the position to 323,843 shares worth $2.34M. The position accounts for 0.03% of the portfolio, ranked #552.

Boothbay Fund Management first reported a position in EPRX in Q4 2025 and has held it in 2 quarters since. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Boothbay Fund Management held 323,843 shares of Eupraxia Pharmaceuticals worth $2.34M as of Q1 2026.
  • Boothbay Fund Management bought 167,512 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $1.35M.
  • Eupraxia Pharmaceuticals made up 0.03% of Boothbay Fund Management's portfolio in Q1 2026, its #552 holding.
  • Boothbay Fund Management first reported a position in Eupraxia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Boothbay Fund Management's 13F filing for Q1 2026, filed 15 May 2026.